Drug news
NICE recommends Lemtrada for relapsing-remitting Multiple Sclerosis- Genzyme + Bayer
In final draft guidance, the National Institute for Health and Care Excellence (NICE) is now recommending the use of Lemtrada (alemtuzumab) from Genzyme/Bayer in the treatment of relapsing-remitting Multiple Sclerosis.
Lemtrada is taken intravenously once a year for two years, the first course being administered for five consecutive days and the second for three consecutive days, allowing patients to lead their lives without treatment for the rest of the time.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.